Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2025-12-24 @ 10:58 PM
NCT ID:
NCT00683969
Eligibility Criteria:
Inclusion Criteria:
* adult patients 18 to 80 years of age;
* diagnosis of myasthenia gravis;
* history of myasthenia weakness involving more than ocular (ie eye) or peri-ocular muscle;
* duration of myasthenia gravis symptoms (including ocular symptoms) \<=10 years;
* prednisone dose \>=20 mg/day (or equivalent alternate-day dose) for \>=4 weeks.
Exclusion Criteria:
* female patients who are pregnant, breastfeeding, or lactating;
* regularly scheduled plasma exchange (PE) or intravenous immunoglobulin (IVIG) treatment, or PE or IVIG treatment within 2 weeks prior to randomization;
* any prior clinically significant use of CellCept or other immunosuppressive therapy (except corticosteroids), or within 8 weeks prior to randomization.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT00683969
Study Brief:
Protocol Section:
NCT00683969